Audra Iness

Prof. Audra Iness

Virginia Commonwealth University (VCU), USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CLChao Li
Chao Li
Audra InessAudra Iness
Audra Iness
JYJennifer Yoon
Jennifer Yoon
JGJohn R. Grider
John R. Grider
KMKarnam S. Murthy
Karnam S. Murthy
JKJohn F. Kuemmerle
John F. Kuemmerle
Increased TGF-β1 and TGF-β1–dependent Collagen I production in intestinal mesenchymal cells result in fibrosis in patients with Montreal B2 fibrostenotic Crohn’s disease. Numerous cytokines, including IL-6, are produced by activated mesenchymal cells themselves and activate STAT3. The aim of the current study was to determine the mechanisms by which STAT-3 activation might result in intestinal fibrosis. Cytokine levels were measured by ELISA. STAT3 and suppressor of cytokine signaling 3 protein levels were measured by immunoblot, STAT3-TGFB1 DNA–binding activity by chromatin immunoprecipitation, and TGFB1 transcriptional activity by luciferase reporter assay. TGF-β1 (TGFB1), Collagen1α1, and connective tissue growth factor (CTGF) gene expression was measured by quantitative RT-PCR. The role of STAT3 activation was determined using STAT3 inhibitor, Stattic, and by transfection of STAT3 mutants. Autocrine production of cytokines was increased in muscle cells of B2 phenotype patients from strictures and normal intestine in the same patient and compared with other Crohn’s phenotypes, ulcerative colitis, and non-Crohn’s patients. A unique pattern of STAT3 phosphorylation emerged: high STAT3(S727) and low STAT3(Y705) in strictures and the opposite in unaffected intestine. TGFB1 transcriptional activity was regulated by phospho-STAT3(S727) and was decreased by Stattic or dominant-negative STAT3(S727A). TGF-β1, COL1A1, and CTGF expression was inhibited by Stattic or dominant-negative STAT3(S727A). Treatment of normal muscle cells with IL-6 or expression of constitutively active STAT3(S727E) phenocopied muscle cells from strictured intestine. Neutralization of autocrine IL-6 reversed STAT3 phosphorylation and normalized expression of TGF-β1 in strictured intestinal muscle. The ability of Stattic to improve development of fibrosis was confirmed in mice with 2,4,6-trinitrobenzenesulfonic acid–induced colitis. We observed a unique phospho-STAT3(S727) response in patients with Montreal B2 Crohn’s disease, particularly in response to IL-6 leading to increased TGF-β1, collagen, and CTGF production in ileal strictures.

28 July 2016 in Nature Communications
Verified
Journal Article
Open access
AMAimee H. Marceau
Aimee H. Marceau
JFJessica G. Felthousen
Jessica G. Felthousen
PGPaul D. Goetsch
Paul D. Goetsch
Audra InessAudra Iness
Audra Iness
HLHsiau-Wei Lee
Hsiau-Wei Lee
ARAimee H. Marceau Hsiau-Wei Lee Sarvind M. Tripathi Seth M. Rubin
Aimee H. Marceau Hsiau-Wei Lee Sarvind M. Tripathi Seth M. Rubin
The MuvB complex recruits transcription factors to activate or repress genes with cell cycle-dependent expression patterns. MuvB contains the DNA-binding protein LIN54, which directs the complex to promoter cell cycle genes homology region (CHR) elements. Here we characterize the DNA-binding properties of LIN54 and describe the structural basis for recognition of a CHR sequence. We biochemically define the CHR consensus as TTYRAA and determine that two tandem cysteine rich regions are required for high-affinity DNA association. A crystal structure of the LIN54 DNA-binding domain in complex with a CHR sequence reveals that sequence specificity is conferred by two tyrosine residues, which insert into the minor groove of the DNA duplex. We demonstrate that this unique tyrosine-mediated DNA binding is necessary for MuvB recruitment to target promoters. Our results suggest a model in which MuvB binds near transcription start sites and plays a role in positioning downstream nucleosomes.

1 October 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Arun SamiduraiArun Samidurai
Arun Samidurai
LXLei Xi
Lei Xi
ADAnindita Das
Anindita Das
Audra InessAudra Iness
Audra Iness
NVNavin G. Vigneshwar
Navin G. Vigneshwar
RKRakesh C Kukreja
Rakesh C Kukreja

11 September 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
Audra InessAudra Iness
Audra Iness
JFJessica Felthousen
Jessica Felthousen
VAVarsha Ananthapadmanabhan
Varsha Ananthapadmanabhan
FSFatmata Sesay
Fatmata Sesay
SSSiddharth Saini
Siddharth Saini
LLLarisa Litovchick
Larisa Litovchick

25 April 2022 in The American Journal of Medicine
Verified
Journal Article
Open access
Audra InessAudra Iness
Audra Iness
JAJefferson O. Abaricia
Jefferson O. Abaricia
WSWendemi Sawadogo
Wendemi Sawadogo
CICaleb M. Iness
Caleb M. Iness
MDMax Duesberg
Max Duesberg
VPVinay Prasad
Vinay Prasad
Health care policymaking during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has questioned the precedent of restricting hospital visitors. We aimed to synthesize available data describing the resulting impact on patient, family/visitor, and health care provider well-being. We systematically reviewed articles from the World Health Organization COVID-19 Global Literature on Coronavirus Disease Database published between December 2019 through April 2021. Included studies focused on hospitalized patients and reported 1 or more prespecified main or secondary outcome (coronavirus disease 2019 [COVID-19] disease transmission, global well-being, mortality, morbidity, or health care resource utilization). Two authors independently extracted data into a standardized form with a third author resolving discrepancies. A total of 1153 abstracts were screened, and 26 final full-text articles were included. Ten studies were qualitative, with 7 cohort studies, and no randomized controlled trials. Critically ill patients were the most represented (12 out of 26 studies). Blanket hospital visitor policies were associated with failure to address the unique needs of patients, their visitors, and health care providers in various clinical environments. Overall, a patient-centered, thoughtful, and nuanced approach to hospital visitor policies is likely to benefit all stakeholders while minimizing potential harms.

6 December 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
CWChristopher S. Williams
Christopher S. Williams
Audra InessAudra Iness
Audra Iness
RBRebecca M. Baron
Rebecca M. Baron
OAOlujimi A. Ajijola
Olujimi A. Ajijola
PHPatrick J. Hu
Patrick J. Hu
MZMone Zaidi
Mone Zaidi
There is growing concern that the physician-scientist is endangered due to a leaky training pipeline and prolonged time to scientific independence (1). The NIH Physician-Scientist Workforce Working Group has concluded that as many as 1,000 individuals will need to enter the pipeline each year to sustain the workforce (2). Moreover, surveys of postgraduate training programs document considerable variability in disposition and infrastructure (3). Programs can be broadly grouped into two classes: physician-scientist training programs (PSTPs) that span residency and fellowship training, and research-in-residency programs (RiRs), which are limited to residency but trainees are able to match into PSTPs upon transitioning to fellowship (Figure 1). Funding sources for RiRs and PSTPs are varied and include NIH KL2 and T32 awards, charitable foundations, philanthropy, and institutional support. Furthermore, standards for research training and tools for evaluating programmatic success are lacking. Here, we share consensus generated from iterative workshops hosted by the Alliance of Academic Internal Medicine (AAIM) and the student-led American Physician Scientists Association (APSA).